Familial Adenomatous Polyposis Medical Services in China

Familial Adenomatous Polyposis (FAP) is a rare, autosomal dominant inherited disorder characterized by the development of hundreds to thousands of colorectal adenomatous polyps, typically beginning in adolescence. Left untreated, these polyps carry an almost 100% lifetime risk of progressing to colorectal cancer—usually by age 40–50. FAP results from germline pathogenic variants in the APC (adenomatous polyposis coli) gene on chromosome 5q21–22, which encodes a tumor suppressor protein critical for regulating β-catenin degradation, cell adhesion, migration, and apoptosis. Loss of functional APC leads to constitutive WNT pathway activation, uncontrolled epithelial proliferation, and rapid adenoma formation throughout the colorectum. A milder variant, attenuated FAP (AFAP), presents with fewer polyps (typically 10–100), later onset (mean age ~55), and lower—but still significantly elevated—cancer risk. Epidemiologically, FAP affects approximately 1 in 7,000 to 1 in 22,000 individuals worldwide, with no ethnic or gender predilection; about 25–30% of cases arise from de novo mutations, meaning affected individuals may be the first in their family with the condition. Key risk factors include having a first-degree relative with FAP (conferring 50% inheritance risk) and confirmed APC mutation status. Extracolonic manifestations are common and clinically significant: duodenal and periampullary adenomas (present in up to 90% of adults with FAP, with 3–5% lifetime risk of duodenal cancer), gastric fundic gland polyps, osteomas, dental anomalies, congenital hypertrophy of the retinal pigment epithelium (CHRPE), desmoid tumors (occurring in 10–20%, often post-surgery and potentially life-threatening due to local invasion), and increased risks of thyroid (especially papillary), brain (medulloblastoma in Turcot syndrome variant), and hepatoblastoma (in young children). Quality of life is profoundly impacted—not only by the psychological burden of lifelong surveillance, high cancer anxiety, and prophylactic surgery decisions, but also by physical consequences: colectomy often necessitates ileorectal anastomosis (IRA) or restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA), both associated with bowel frequency, urgency, nocturnal seepage, sexual dysfunction, and infertility concerns (particularly in women after IPAA or desmoid-related pelvic surgery). Desmoid disease can cause chronic pain, organ compression, and functional impairment. Genetic counseling, early endoscopic screening starting at age 10–12, and timely surgical intervention remain cornerstones of management. With comprehensive care—including genetic testing, coordinated gastroenterology, surgical oncology, and psychosocial support—life expectancy approaches normal, though lifelong multidisciplinary follow-up is essential.

Familial Adenomatous Polyposis (FAP) is an autosomal dominant inherited disorder characterized by the development of hundreds to thousands of colorectal adenomatous polyps, typically beginning in adolescence. The overwhelming majority of FAP cases—over 95%—are caused by pathogenic germline variants in the APC (adenomatous polyposis coli) gene, located on chromosome 5q21–22. The APC gene encodes a multifunctional tumor suppressor protein critical for regulating β-catenin degradation within the Wnt signaling pathway. Loss-of-function mutations in APC lead to constitutive activation of Wnt signaling, uncontrolled epithelial cell proliferation, and impaired apoptosis—culminating in early-onset adenoma formation throughout the colorectum. Over 1,000 distinct APC variants have been documented, including nonsense, frameshift, splice-site, and large genomic deletions; genotype–phenotype correlations exist, with mutations between codons 1250 and 1464 associated with classic severe polyposis, while mutations at the extreme 5′ or 3′ ends or in exon 9 may correlate with attenuated FAP (AFAP), featuring fewer polyps (typically <100), later onset (mean age ~55 years), and proximal colonic predominance. Rarely, biallelic APC mutations cause congenital hypertrophy of the retinal pigment epithelium (CHRPE) and desmoid tumors without polyposis (autosomal recessive inheritance pattern). A small subset of clinically FAP-like patients (10–20% of APC-negative cases) harbor pathogenic variants in the MUTYH gene, resulting in MUTYH-Associated Polyposis (MAP), an autosomal recessive condition. Biallelic MUTYH mutations impair base excision repair, leading to G:C→T:A transversions in oncogenes such as KRAS and APC itself—thus phenocopying FAP but with later onset and variable expressivity.

While genetic predisposition is necessary and sufficient for FAP manifestation, disease expression and progression are modulated by several modifiers. No environmental triggers initiate FAP—polyp development is genetically predetermined—but certain factors influence polyp burden, growth rate, and extracolonic manifestations. Smoking has been associated with earlier onset of colorectal cancer in FAP patients and increased risk of duodenal adenomas. High dietary intake of red and processed meats, saturated fats, and low fiber consumption may accelerate adenoma progression, though evidence is less robust than in sporadic colorectal cancer. Obesity and metabolic syndrome correlate with increased duodenal polyp burden and severity of periampullary lesions. Chronic NSAID use (e.g., sulindac, celecoxib) demonstrates chemopreventive effects by inhibiting COX-2–mediated prostaglandin synthesis and inducing apoptosis in adenomatous tissue; however, NSAIDs do not eliminate polyps or prevent cancer and are adjunctive only. Hormonal factors appear relevant: estrogen exposure may confer modest protection against colorectal cancer in female FAP carriers, whereas oral contraceptive use has shown inconsistent associations. Notably, physical activity and diets rich in calcium, vitamin D, and cruciferous vegetables show epidemiologic support for attenuating polyp growth, though randomized trial data remain limited.

Genetic risk factors extend beyond the primary APC or MUTYH mutation. Modifier genes—including polymorphisms in inflammatory cytokines (e.g., IL-10, TNF-α), DNA repair enzymes (e.g., XRCC1), and metabolic enzymes (e.g., NAT2)—may influence penetrance, polyp number, and cancer risk. Family history remains the strongest clinical risk predictor: first-degree relatives of an affected individual carry a 50% risk of inheriting the pathogenic variant. Penetrance of colorectal adenomas in APC carriers approaches 100% by age 40; cumulative lifetime risk of colorectal cancer exceeds 90% without intervention. Extracolonic manifestations—including duodenal/periampullary adenomas (up to 90%), gastric fundic gland polyps (nearly universal), desmoid tumors (10–20%), thyroid carcinoma (1–2%, predominantly papillary), brain tumors (medulloblastoma in Turcot syndrome variant), and osteomas—further define the FAP phenotype and contribute to morbidity and mortality. Environmental exposures such as ionizing radiation may potentiate desmoid tumor development, particularly postoperatively. Importantly, no known infectious, dietary, or lifestyle factor can prevent or reverse the underlying genetic defect; therefore, surveillance and prophylactic colectomy remain cornerstone interventions. Genetic counseling and predictive testing for at-risk relatives starting at age 10–12 years are essential components of management in gastroenterology practice.

Familial Adenomatous Polyposis (FAP) is an autosomal dominant inherited disorder caused by germline pathogenic variants in the APC (adenomatous polyposis coli) gene, located on chromosome 5q21–22. It is characterized by the development of hundreds to thousands of colorectal adenomatous polyps beginning in adolescence or early adulthood. While FAP itself is not symptomatic in its earliest stages, clinical manifestations emerge as polyp burden increases and dysplasia progresses—typically between ages 10 and 30 years. Early symptoms are often subtle and nonspecific, frequently overlooked or misattributed to benign gastrointestinal conditions. Patients may report intermittent, mild abdominal discomfort or cramping, particularly in the lower abdomen; occasional bloating; or a vague sense of altered bowel habit—including mild constipation or looser stools without overt diarrhea. Rectal bleeding—often occult rather than gross—is among the earliest objective signs, detectable only via fecal immunochemical testing (FIT) or guaiac-based stool testing. Iron-deficiency anemia secondary to chronic occult blood loss may manifest insidiously as fatigue, pallor, exertional dyspnea, or reduced exercise tolerance, especially in adolescents and young adults with otherwise unexplained microcytic hypochromic anemia. Notably, many individuals remain entirely asymptomatic during the early polyposis phase, underscoring the critical importance of genetic screening and surveillance in at-risk family members.

Typical symptoms emerge as polyp number and size increase, usually by the second or third decade. The hallmark presentation includes recurrent episodes of visible rectal bleeding—ranging from streaks on toilet paper to frank hematochezia—often accompanied by mucous discharge. Patients commonly develop progressive changes in bowel habits: persistent diarrhea, urgency, tenesmus, or alternating constipation and diarrhea due to luminal obstruction or inflammatory changes within large polyp clusters. Abdominal pain becomes more frequent and localized, sometimes mimicking irritable bowel syndrome or diverticular disease. In advanced cases, patients may experience weight loss, anorexia, or low-grade fevers attributable to chronic mucosal inflammation or early malignant transformation. A subset develops palpable abdominal masses—particularly in the left colon or rectum—though this is uncommon before malignancy arises.

Accompanying extracolonic manifestations are integral to FAP diagnosis and reflect the systemic nature of APC dysfunction. Gastric fundic gland polyps occur in >90% of patients, typically asymptomatic but occasionally associated with gastric dysplasia. Duodenal and periampullary adenomas are present in up to 90% of adults with FAP and represent the leading cause of non-colorectal cancer mortality; they may cause biliary colic, obstructive jaundice, or pancreatitis if ampullary involvement leads to ductal obstruction. Desmoid tumors—benign but locally aggressive fibroblastic proliferations—occur in 10–20% of FAP patients, most commonly intra-abdominally (mesenteric or retroperitoneal), causing pain, bowel obstruction, ureteral compression, or vascular compromise. Osteomas (especially mandibular), dental abnormalities (supernumerary teeth, odontomas), congenital hypertrophy of the retinal pigment epithelium (CHRPE), epidermoid cysts, and thyroid carcinoma (predominantly papillary) are well-documented associations requiring multidisciplinary monitoring.

Complications arise predictably without intervention. Colorectal cancer develops in nearly 100% of untreated individuals by age 40–50 years, with median age at diagnosis around 39 years. Cancer risk correlates strongly with polyp burden and histologic grade; high-grade dysplasia in ≥20% of polyps significantly elevates imminent carcinoma risk. Desmoid tumors may cause life-threatening complications including small bowel obstruction, mesenteric ischemia, or superior mesenteric vein thrombosis. Duodenal adenocarcinoma carries a 5–10% lifetime risk and accounts for ~3% of FAP-related deaths. Other serious complications include gastric adenocarcinoma (rare), hepatoblastoma in children <5 years (associated with specific APC mutations), brain tumors (Turcot syndrome variant), and severe anemia requiring transfusion support.

Diagnosis relies on integration of clinical, endoscopic, histopathologic, and genetic data. Colonoscopy remains the gold standard for initial evaluation: visualization of ≥100 colorectal adenomas confirms classic FAP; ≥20 adenomas warrants APC gene testing even without family history. Histology demonstrates tubular or tubulovillous adenomas with varying degrees of dysplasia. Upper endoscopy (esophagogastroduodenoscopy) assesses gastric and duodenal polyps using Spigelman staging to guide surveillance intervals. Genetic testing—via next-generation sequencing of APC—is recommended for all index cases and predictive testing for at-risk relatives starting at age 10–12 years. If APC testing is negative but clinical suspicion remains high, analysis for MUTYH-associated polyposis (biallelic MUTYH variants) should be pursued. Radiographic imaging (CT/MRI) evaluates desmoids, while thyroid ultrasound and dermatologic examination screen for extracolonic features.

Differential diagnosis includes several polyposis syndromes and sporadic conditions. MUTYH-Associated Polyposis (MAP) presents similarly but follows autosomal recessive inheritance and typically manifests later (mean age 45–55 years) with 10–100 adenomas. Serrated Polyposis Syndrome (SPS) features numerous serrated polyps (hyperplastic, sessile serrated, traditional serrated adenomas) without APC mutations; it lacks extracolonic manifestations and has distinct cancer risk profiles. Lynch syndrome may rarely present with multiple adenomas but is distinguished by mismatch repair deficiency, predominant right-sided cancers, and absence of florid polyposis. Juvenile Polyposis Syndrome (JPS) involves hamartomatous juvenile polyps, often with GI bleeding and protein-losing enteropathy, and is linked to SMAD4 or BMPR1A mutations. Peutz-Jeghers Syndrome features mucocutaneous pigmentation and hamartomatous polyps with characteristic 'arborizing' smooth muscle bundles. Sporadic adenomatous polyposis must also be considered—though rare beyond age 60 and lacking familial clustering or extracolonic features. Accurate differentiation guides surveillance intensity, surgical timing, and genetic counseling, making comprehensive phenotyping and molecular testing indispensable in the gastroenterology setting.

Familial Adenomatous Polyposis (FAP) is an autosomal dominant inherited disorder caused by germline pathogenic variants in the APC gene, characterized by the development of hundreds to thousands of colorectal adenomatous polyps beginning in adolescence. Without intervention, the cumulative risk of colorectal cancer approaches 100% by age 40–50. Management requires a multidisciplinary, lifelong strategy coordinated primarily by gastroenterology, surgical oncology, and genetic counseling services. Treatment encompasses surveillance, chemoprevention, endoscopic management, and definitive surgical resection—tailored to disease burden, genotype-phenotype correlations, patient age, and comorbidities.

Conservative treatment in FAP centers on rigorous endoscopic surveillance and risk mitigation rather than curative intent. Colonoscopy should commence at age 10–12 years, repeated annually until polyposis is evident; once dense polyposis develops (typically >20–30 adenomas or large (>6 mm) or dysplastic lesions), prophylactic colectomy is strongly recommended. Upper gastrointestinal surveillance—including esophagogastroduodenoscopy (EGD)—begins at age 20–25 and is repeated every 1–5 years depending on duodenal polyp burden (Spigelman stage). Surveillance for extracolonic manifestations—including fundic gland polyps, gastric adenomas, periampullary adenomas, desmoid tumors, thyroid carcinoma, and brain tumors (Turcot syndrome)—is integral. Lifestyle modifications—including smoking cessation, limiting red/processed meat intake, maintaining healthy BMI, and regular physical activity—are advised to reduce secondary carcinogenic stimuli, though evidence for their impact on polyp progression remains observational.

Pharmacologic intervention serves as adjunctive chemoprevention, not replacement for surgery. Nonsteroidal anti-inflammatory drugs (NSAIDs), particularly sulindac and celecoxib, have demonstrated efficacy in reducing colorectal and duodenal polyp number and size in randomized controlled trials. Sulindac (200 mg twice daily) reduces rectal polyp burden by ~30–50% in patients with retained rectum post-colectomy (e.g., after ileorectal anastomosis), while celecoxib (400 mg twice daily) showed significant regression of duodenal adenomas in FAP patients in the APC trial. However, long-term NSAID use carries risks—including gastrointestinal ulceration, renal impairment, and cardiovascular events—and is contraindicated in patients with aspirin hypersensitivity or advanced renal disease. Aspirin has shown modest benefit in sporadic adenoma prevention but lacks robust FAP-specific data. Emerging agents—including COX-2 inhibitors combined with EGFR inhibitors (e.g., erlotinib) and novel Wnt pathway modulators—are under investigation in early-phase trials but remain investigational outside clinical research settings.

Surgical treatment remains the cornerstone of FAP management. Total proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the preferred procedure for most patients with established polyposis, offering near-complete elimination of colorectal cancer risk while preserving continence and avoiding a permanent stoma. Alternative options include total colectomy with ileorectal anastomosis (IRA), reserved for select patients with minimal rectal polyp burden (<5–10 small adenomas) and excellent compliance with lifelong rectal surveillance. IRA carries a 10–25% cumulative risk of rectal cancer over 20 years and mandates annual high-definition rectoscopy. For patients with severe desmoid disease, unresectable duodenal polyposis, or contraindications to IPAA, total proctocolectomy with end-ileostomy may be indicated. Prophylactic gastroduodenectomy is rarely performed but considered for Spigelman stage IV disease unresponsive to endoscopic therapy. All surgical candidates require preoperative genetic confirmation, comprehensive upper GI evaluation, and assessment for desmoid tumor risk (e.g., family history, APC mutation location—codon 1444–1578 confers higher desmoid risk).

China offers distinct advantages in FAP care, particularly through its integrated national screening infrastructure and rapidly advancing endoscopic-surgical capabilities. Major academic centers—including Peking Union Medical College Hospital, Zhongshan Hospital (Fudan University), and West China Hospital—operate dedicated hereditary gastrointestinal cancer clinics with standardized protocols aligned with international guidelines (ESMO, NCCN, ESGE). High-volume endoscopy units routinely perform advanced techniques such as chromoendoscopy, narrow-band imaging (NBI), and endoscopic mucosal resection (EMR) for duodenal and gastric adenomas. Robotic-assisted IPAA is increasingly available in tier-1 hospitals, demonstrating reduced intraoperative blood loss and shorter hospital stays compared to laparoscopic approaches in recent cohort studies. Moreover, China’s National Medical Products Administration (NMPA) has expedited approval pathways for targeted therapies and biosimilars, improving access to celecoxib and enabling participation in global phase II/III trials of Wnt inhibitors. Genetic testing turnaround time has decreased to <14 days in accredited laboratories, facilitating timely risk stratification. Importantly, China’s tiered healthcare system enables seamless referral from community health centers to provincial cancer hospitals, ensuring continuity across surveillance, surgery, and long-term follow-up.

Post-treatment recovery necessitates structured, lifelong follow-up. After IPAA, patients undergo pouchoscopy at 6–12 months, then every 1–3 years depending on pouch inflammation or dysplasia. IRA patients require annual high-definition rectoscopy with random biopsies. Duodenal surveillance continues every 6–12 months for Spigelman stage III–IV, with endoscopic ampullectomy or endoscopic retrograde cholangiopancreatography (ERCP)-guided interventions for ampullary lesions. Patients should receive annual thyroid ultrasound and abdominal MRI if desmoid risk is elevated. Psychosocial support—including genetic counseling for at-risk relatives and fertility counseling (especially pre-IPAA, given potential impact on pelvic anatomy)—is essential. Nutritional guidance focuses on hydration, soluble fiber supplementation (e.g., psyllium) to regulate pouch function, and avoidance of excessive caffeine/alcohol that may exacerbate pouchitis. Pregnancy counseling is recommended for women of childbearing age, as desmoid tumors may flare during gestation. Finally, cascade genetic testing of first-degree relatives is mandatory: APC testing should begin at age 10, with colonoscopy initiation by age 12 regardless of test result if testing is declined or unavailable. Adherence to this comprehensive, individualized framework significantly reduces mortality and optimizes quality of life in FAP.